EA201500293A1 - Антихолинэргическая нейропротективная композиция и способы - Google Patents

Антихолинэргическая нейропротективная композиция и способы

Info

Publication number
EA201500293A1
EA201500293A1 EA201500293A EA201500293A EA201500293A1 EA 201500293 A1 EA201500293 A1 EA 201500293A1 EA 201500293 A EA201500293 A EA 201500293A EA 201500293 A EA201500293 A EA 201500293A EA 201500293 A1 EA201500293 A1 EA 201500293A1
Authority
EA
Eurasian Patent Office
Prior art keywords
relates
antiholinergic
methods
iaea
blood
Prior art date
Application number
EA201500293A
Other languages
English (en)
Other versions
EA038489B1 (ru
Inventor
Кэтлин Э. Клэренс-Смит
Томас Н. Чейс
Original Assignee
Чейс Фамасьютикалз Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чейс Фамасьютикалз Корпорейшн filed Critical Чейс Фамасьютикалз Корпорейшн
Publication of EA201500293A1 publication Critical patent/EA201500293A1/ru
Publication of EA038489B1 publication Critical patent/EA038489B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение касается фармацевтической композиции, содержащей пропиверин, троспий или гликопирролат; и неантихолинергическое противорвотное средство. Оно также касается фармацевтической композиции, содержащей высокую дозировку солифенацина или его фармацевтически приемлемых солей; и неантихолинергическое противорвотное средство. Также описаны фармацевтические композиции, содержащие высокую дозировку нсПАХС, для применения в целях увеличения концентрации ИАХЭ в крови и для борьбы с нейродегенерацией. Настоящее изобретение также касается способа индуцирования нейропротективного действия и борьбы с нейродегенерацией у пациентов, страдающих деменцией по типу болезни Альцгеймера, а также способа повышения концентрации ингибитора ацетилхолинэстеразы (ИАХЭ) в крови у пациента (человека), которому вводят дозу ИАХЭ.
EA201500293A 2012-09-05 2013-09-05 Антихолинэргическая нейропротективная композиция и способы EA038489B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261697069P 2012-09-05 2012-09-05
US201261696978P 2012-09-05 2012-09-05
US201261697021P 2012-09-05 2012-09-05
US201261697039P 2012-09-05 2012-09-05
PCT/US2013/058172 WO2014039627A1 (en) 2012-09-05 2013-09-05 Anticholinergic neuroprotective composition and methods

Publications (2)

Publication Number Publication Date
EA201500293A1 true EA201500293A1 (ru) 2015-07-30
EA038489B1 EA038489B1 (ru) 2021-09-06

Family

ID=50237591

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201500293A EA038489B1 (ru) 2012-09-05 2013-09-05 Антихолинэргическая нейропротективная композиция и способы

Country Status (14)

Country Link
US (4) US9561218B2 (ru)
EP (2) EP2892514A4 (ru)
JP (4) JP2015531346A (ru)
KR (2) KR20150048888A (ru)
CN (1) CN104768540A (ru)
AU (1) AU2013312749B2 (ru)
BR (3) BR112015004902A2 (ru)
CA (1) CA2882407C (ru)
EA (1) EA038489B1 (ru)
HK (1) HK1210947A1 (ru)
IL (3) IL237176B (ru)
IN (1) IN2015DN01706A (ru)
MX (2) MX2015002864A (ru)
WO (1) WO2014039627A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969402B2 (en) * 2006-11-15 2015-03-03 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
JP2012533621A (ja) 2009-07-22 2012-12-27 ピュアテック ベンチャーズ ムスカリン性受容体活性化によって改善される疾患の治療のための方法および組成物
BR112015002832B1 (pt) * 2012-08-09 2022-08-16 Chase Pharmaceuticals Corporation Composição farmacêutica e uso de um haleto de 1-alquil-1-metil-4-[(2,2-difenil-2-propoxi) acetoxi]piperidínio
KR20150048888A (ko) * 2012-09-05 2015-05-07 체이스 파마슈티칼스 코포레이션 항콜린 신경보호 조성물 및 그 방법
US10149828B2 (en) * 2015-01-09 2018-12-11 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
EP3265128A4 (en) 2015-03-06 2018-09-12 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system muscarinic agonist combination
US10307409B2 (en) 2015-03-06 2019-06-04 Chase Pharmaceuticals Corporation Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
WO2017015349A1 (en) * 2015-07-20 2017-01-26 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
CA2996719A1 (en) * 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
EP4019018A1 (en) * 2015-09-11 2022-06-29 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
US10357487B2 (en) * 2015-12-03 2019-07-23 Sidney J. Goldfarb Combinations of acetylcholinesterase inhibitors and muscarinic agonists and methods of use thereof
WO2017147104A1 (en) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combinations
TW201821068A (zh) * 2016-10-28 2018-06-16 美商查斯製藥公司 美金剛胺(memantine)組合及用途
EP3589369A4 (en) 2017-01-09 2020-03-18 DAS-MG, Inc. USE AND COMPOSITION FOR TREATING MYASTHENIA GRAVIS AND OTHER MYASTHENIC SYNDROME
WO2018140412A1 (en) * 2017-01-24 2018-08-02 Gt Biopharma, Inc. Neostigmine combination and compositions
AU2018243718A1 (en) 2017-03-27 2019-11-07 Chase Therapeutics Corporation Compositions and methods for treating synucleinopathies
CN115581696A (zh) 2018-09-28 2023-01-10 卡鲁娜治疗学有限公司 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
US11759451B2 (en) 2020-09-15 2023-09-19 City University Of Hong Kong Therapeutic potential of glycopyrrolate and mexiletine for nervous system injury
US20220241254A1 (en) * 2021-01-29 2022-08-04 Qaam Pharmaceuticals, Llc Fixed dose combination of cholinesterase inhibitor and a quaternary ammonium antimuscarinic agent to treat neurodegenerative cognitive disorders
US20220304946A1 (en) * 2021-03-28 2022-09-29 Muhammad Imran Khan Trans-anethole ((e)-1-methoxy-4- (1-propenyl) benzene), a new and potent inhibitor of prolyl endopeptidase

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3480626A (en) 1967-05-18 1969-11-25 Chem Fab Dr R Pfleger Certain azoniaspironortropine derivatives
GB1204580A (en) 1968-10-05 1970-09-09 Aspro Nicholas Ltd Pharmaceutical dosage forms
US3576388A (en) 1968-12-05 1971-04-27 Stauffer Wacker Silicone Corp Electrical cable
DD106643A1 (ru) 1973-07-12 1974-06-20
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
GB9423588D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
IL128877A0 (en) 1997-07-09 2000-01-31 Axonyx And Nat Inst Of Health Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
EP0976404A3 (en) 1998-07-30 2001-06-27 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
ES2237163T3 (es) 1998-10-01 2005-07-16 Novartis Ag Nuevas formulaciones orales de revastigmina de liberacion controlada.
CN1285348A (zh) 1999-08-20 2001-02-28 广东康美药业股份有限公司 盐酸丙哌维林合成工艺
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
CA2436083A1 (en) 2001-02-08 2002-09-19 Schering Corporation Use of dual h3/m2 antagonists in the treatment of cognition deficit disorders
US7427280B2 (en) 2002-09-06 2008-09-23 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by delivering drugs to various nerves or tissues
CN1520818A (zh) 2003-02-09 2004-08-18 山东绿叶天然药物研究开发有限公司 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
KR100500760B1 (ko) 2003-07-22 2005-07-14 동방에프티엘 주식회사 염산 프로피베린의 제조방법
KR100510788B1 (ko) 2003-07-22 2005-08-26 동방에프티엘 주식회사 프로필벤질릭산 에스터로부터 염산 프로피베린의 제조방법
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
WO2005073198A1 (en) 2004-01-16 2005-08-11 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
AR051950A1 (es) 2004-11-10 2007-02-21 Osmotica Pharmaceutical Argent Comprimido multicapa con capas que se separan
US7915303B2 (en) * 2005-03-24 2011-03-29 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use
US7390816B2 (en) 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
US20070224259A1 (en) 2005-09-21 2007-09-27 Gupta Anil K Anti-inflammatory pharmaceutical composition
WO2007047010A2 (en) * 2005-10-20 2007-04-26 Indevus Pharmaceuticals, Inc. Anti-emetic uses of cannabinoid analogs
WO2007055806A1 (en) * 2005-10-31 2007-05-18 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r,4r)-δ8-tetrahydrocannabinol-11-oic acids
US20070173528A1 (en) 2005-12-21 2007-07-26 Nurit Perlman Process for preparing solifenacin
AU2007243490A1 (en) 2006-04-21 2007-11-08 Wyeth Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof
DE602007013559D1 (de) 2006-07-07 2011-05-12 Univ Aarhus Nanoteilchen zur abgabe von nukleinsäure
US8097633B2 (en) 2006-11-15 2012-01-17 Rich Steven A Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
US20110201597A1 (en) * 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
US8877768B2 (en) 2009-09-18 2014-11-04 Chase Pharmaceuticals Corporation Method and composition for treating alzheimer-type dementia
CA2718411C (en) * 2008-03-27 2016-02-16 Chase Pharmaceuticals Corporation Use and composition for treating dementia
WO2009139002A2 (en) 2008-05-12 2009-11-19 Msn Laboratories Limited An improved process for the preparation of solifenacin and its pharmaceutically acceptable salts thereof
EP2451809B1 (en) 2009-07-09 2016-10-12 KRKA, D.D., Novo Mesto A process for the preparation and purification of solifenacin salts
KR20120023059A (ko) 2010-03-15 2012-03-12 라마크리시나 라메샤 안다가 프로피베린 염산염의 합성
WO2011125763A1 (ja) * 2010-03-31 2011-10-13 小野薬品工業株式会社 手足症候群の予防および／または治療剤
KR101149821B1 (ko) 2010-04-05 2012-05-24 하나제약 주식회사 디페닐아세테이트 유도체의 새로운 제조방법
WO2012001481A1 (en) 2010-06-28 2012-01-05 Aurobindo Pharma Limited Novel process for the preparation of solifenacin succinate
CN102218063B (zh) 2011-04-12 2013-03-13 贵州神奇制药有限公司 盐酸丙哌维林药物的制备方法和产品及其检测方法
KR20150048888A (ko) * 2012-09-05 2015-05-07 체이스 파마슈티칼스 코포레이션 항콜린 신경보호 조성물 및 그 방법

Also Published As

Publication number Publication date
MX2015002864A (es) 2015-07-14
KR20150048888A (ko) 2015-05-07
JP2021191759A (ja) 2021-12-16
WO2014039627A1 (en) 2014-03-13
IL237176A0 (en) 2015-04-30
US20170087142A1 (en) 2017-03-30
IL268603B (en) 2021-03-25
AU2013312749A2 (en) 2015-04-16
US9561218B2 (en) 2017-02-07
JP2020105212A (ja) 2020-07-09
JP2015531346A (ja) 2015-11-02
BR122016020433A2 (pt) 2019-08-27
US20190365736A1 (en) 2019-12-05
JP2018150314A (ja) 2018-09-27
US20190000826A1 (en) 2019-01-03
IN2015DN01706A (ru) 2015-05-22
BR122016020434A2 (pt) 2019-08-27
HK1210947A1 (en) 2016-05-13
KR20200065113A (ko) 2020-06-08
CA2882407A1 (en) 2014-03-13
EP2892514A1 (en) 2015-07-15
CA2882407C (en) 2022-11-15
EP2892514A4 (en) 2016-04-13
IL237176B (en) 2018-02-28
AU2013312749A1 (en) 2015-04-02
US9913836B2 (en) 2018-03-13
BR112015004902A2 (pt) 2017-07-04
EA038489B1 (ru) 2021-09-06
MX2020002113A (es) 2021-09-08
EP4035668A1 (en) 2022-08-03
AU2013312749B2 (en) 2018-01-18
IL268603A (en) 2019-10-31
CN104768540A (zh) 2015-07-08
IL257150A (en) 2018-03-29
US20150231122A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
EA201500293A1 (ru) Антихолинэргическая нейропротективная композиция и способы
EA201491329A1 (ru) 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
EA201590453A1 (ru) Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
RU2013121788A (ru) Ингибиторы репликации вич
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
EA201691375A1 (ru) (2s)-n-[(1s)-1-циано-2-фенилэтил]-1,4-оксазепан-2-карбоксамиды в качестве ингибиторов дипептидилпептидазы i
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
RU2015107877A (ru) Способы лечения болезни альцгеймера и фармацевтические композиции
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
EA201390332A1 (ru) Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
BR112015010396A2 (pt) terapia de combinação
EA201270492A1 (ru) Соединения для лечения дислипидемии и связанных с ней заболеваний
EA201590697A1 (ru) Производные кетамина
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA200870469A1 (ru) Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение
EA201591328A1 (ru) Замещенные гетероциклом тетрациклические соединения и способы их применения для лечения вирусных заболеваний
EA201300988A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол